

*Alexandra Carina Gruber*

## **Biotech Funding Trends**

Insights from Entrepreneurs and Investors



**WILEY-  
BLACKWELL**

WILEY-VCH Verlag GmbH & Co. KGaA



*Alexandra Carina Gruber*  
**Biotech Funding Trends**

## ***Related Titles***

Behme, S.

### **Manufacturing of Pharmaceutical Proteins**

2009

ISBN: 978-3-527-32444-6

Borbye, L.

### **Industry Immersion Learning**

**Biotechnology Cases for Graduate Students in Science and Business**

2009

ISBN: 978-3-527-32408-8

Wink, M. (ed.)

### **An Introduction to Molecular Biotechnology**

**Molecular Fundamentals, Methods and Applications in Modern Biotechnology**

2006

ISBN: 978-3-527-31412-6

*Alexandra Carina Gruber*

## **Biotech Funding Trends**

Insights from Entrepreneurs and Investors



**WILEY-  
BLACKWELL**

WILEY-VCH Verlag GmbH & Co. KGaA

#### The Author

**Dr. Alexandra Carina Gruber**  
Vienna, Austria

#### Cover

Cover picture with kind permission of *onepharm Research & Development GmbH*, Vienna.

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:**  
applied for

**British Library Cataloguing-in-Publication Data**  
A catalogue record for this book is available from the British Library.

**Bibliographic information published by the Deutsche Nationalbibliothek**  
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Editing** Gabriele Berghammer, the text clinic,  
Vienna

**Typesetting** Thomson Digital, Noida, India

**Printing** betz-druck GmbH, Darmstadt

**Binding** Litges & Dopf Buchbinderei GmbH,  
Heppenheim

**Cover Design** Adam-Design, Weinheim  
Alexander Schatek, Wr. Neustadt

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**ISBN:** 978-3-527-32435-4

*For my parents  
who were the most important teachers  
during much of my own development*





*“It is not the strongest of the species that survive,  
nor the most intelligent,  
but the ones most responsive to change.” (Charles Darwin)*



## Contents

**Preface** XIII

**Acknowledgments** XV

**Limit of Liability/Disclaimer of Warranty** XVII

**Executive Summary** 1

<b>1</b>	<b>Introduction</b>	7
1.1	Development of the Private Equity and Venture Capital Market	7
1.1.1	Definition	7
1.1.2	Historical Background	10
1.1.3	The Challenges to Private Equity in Europe	12
1.1.4	Private Equity and Venture Capital Performance in Europe by Country	12
1.1.5	The Future of Private Equity and Venture Capital in Europe	13
1.2	Development of the Biotech Industry	14
1.2.1	Definition	14
1.2.2	Historical Background	16
1.2.3	Financing Biotech Start-ups	18
1.2.4	Exit Routes in the Biotech Industry	22
1.2.5	The Challenges to European Biotech	23
1.2.6	The Future of the European Biotech Industry	23
<b>2</b>	<b>Methodology</b>	27
2.1	Formulating the Research Goal	27
2.1.1	The Entrepreneur's Dilemma	27
2.1.2	The Investor's Dilemma	28
2.1.3	Financing Models	28
2.1.4	Interpersonal Relationships and Cooperations	30
2.1.5	Practical Guidelines for Entrepreneurs and Venture Capitalists	30
2.2	Conducting the Study	31

2.2.1	Qualitative Interviews	31
2.2.2	Selection of Interview Partners	31
2.3	Evaluating the Results	33
<b>3</b>	<b>Data Analysis and Interpretation of Results</b>	<b>35</b>
3.1	Description of Interview Partners	35
3.1.1	Entrepreneurs	35
3.1.2	Venture Capitalists	36
3.1.3	Other Investors	36
3.2	Major Characteristics of an Entrepreneur	36
3.2.1	The Dual Role of the Entrepreneur	37
3.3	Major Characteristics of a Venture Capitalist	38
3.3.1	Global Reach of the Fund	39
3.4	The Most Important Partnering Criteria	40
3.4.1	The Entrepreneur's Perspective	41
3.4.2	The Venture Capitalist's Perspective	41
3.4.3	The Perspective of Other Investors	42
3.5	Financing Models	42
3.5.1	Most Important Financing Models	43
3.5.2	New and Creative Financing Approaches	50
3.5.3	Differences Between Early- and Late-stage Financing	52
3.5.4	Differences Between Early- and Late-stage Valuation Techniques	53
3.6	Biotech Research Areas	58
3.6.1	Vaccines	59
3.6.2	Biotech Drug Development or Medical Technology and Devices?	60
3.7	Alliances and Funding in the Early Stage	61
3.7.1	Networking Between Venture Capitalists and Universities and Their Scientists	61
3.7.2	The Role of Government Grants	63
3.7.3	The Role of Business Angels	65
3.7.4	Preferred Deal Structure	67
3.7.5	Structuring the Board of Directors	68
3.8	Alliances and Funding in the Late Stage	70
3.8.1	Networking with Corporate Venture Capitalists	70
3.8.2	The Role of Banks as Capital Investors	73
3.8.3	The Importance of Milestone Payments	74
3.9	Exit Routes	74
3.9.1	Exit Preferences	74
3.9.2	The Role of New Markets	76
3.9.3	Prominent European IPO Success Stories	77
3.10	Primary Causes of Failure	78
3.10.1	The Entrepreneur's Perspective	78
3.10.2	The Venture Capitalist's Perspective	79
3.10.3	The Perspective of Other Investors	79
3.11	Best-practice Countries for Funding Biotech Start-ups	80

3.11.1	The Entrepreneur's Perspective	80
3.11.2	The Venture Capitalist's Perspective	81
3.11.3	The Perspective of Other Investors	81
3.12	Most Striking Differences between the US and European Venture Capital Markets	82
<b>4</b>	<b>Biotech Case Studies</b>	<b>87</b>
4.1	AUSTRIANOVA Biomanufacturing AG	87
4.2	AVIR Green Hills Biotechnology AG	90
4.3	EUCODIS GmbH	96
4.4	Intercell AG	103
4.5	onepharm Research & Development GmbH	111
<b>5</b>	<b>Summary and Conclusions</b>	<b>117</b>
5.1	The Challenge: When Science Meets Business	117
5.2	Checklists	118
5.2.1	Checklists for the Biotech Entrepreneur	118
5.2.2	Checklist for the Investor	124
5.3	Final Observations	127
<b>6</b>	<b>Outlook and Recommendations</b>	<b>131</b>
	<b>Epilogue</b>	<b>133</b>
	<b>References</b>	<b>137</b>
	<b>Appendix A: List of Abbreviations</b>	<b>141</b>
	<b>Appendix B: Glossary</b>	<b>145</b>
	<b>Appendix C</b>	<b>163</b>
C.1	Overview of Biotech Companies Mentioned in This Book	163
C.2	Overview of Venture Capital Companies Mentioned in This Book	165
	<b>Appendix D: Questionnaires</b>	<b>167</b>
D.1	Questionnaire for the Entrepreneur	167
D.2	Questionnaire for the Venture Capitalist	173
D.3	Questionnaire for the Group of Other Investors	180
	<b>Index</b>	<b>187</b>



## Preface

The European biotech industry has long lagged behind its US counterpart. For most of Europe, the same holds true for private equity and venture capital (VC) spending on innovative start-ups. In recent years, however, the European biotech industry has improved its competitive position vis-à-vis the US, and so has the development of the private equity and VC market. Despite this positive trend, only a small fraction of available capital is invested in biotech start-ups – probably because there is hardly an area more complex, more globally oriented, more time-consuming, and more risky than biotech. As a result, many biotech start-ups are still struggling for survival, particularly in cultures that are less entrepreneurially and private-equity driven.

Has venture capital indeed developed into the dominant financing form for biotech, as it had for other start-up industries, such as information technology? How do above trends affect the interaction between European entrepreneurs, venture capitalists, and other investors? Is the value of venture capital perceived differently between entrepreneurs and investors? Are there any other important financial tools for biotech start-ups? What are the most important advantages and shortcomings of the different financing forms available? What makes the ideal entrepreneur or investor? Why do so many biotech start-ups fail? Can improved communication between entrepreneurs and their investors as well as among investors themselves help foster mutual understanding and lead to more successful long-term partnerships?

Answers to these and other questions about the interpersonal and financial aspects of starting a biotech company were obtained by conducting qualitative interviews with three groups of interview partners, i.e., entrepreneurs, venture capitalists, and other investors. The results of this prospective research study are reported in this book. Entrepreneurs and venture capitalists both inhabit two complex and differing ecosystems with many important, but often opaque, rules and interactions. In view of their different backgrounds, entrepreneurs and investors need to first find a way to understand – and begin to use – the language spoken by their respective counterparts. Interests between different groups of investors, too, can differ substantially. It is therefore nothing short of a challenge to reconcile the often diverging interests of all key players involved in starting a biotech company.

By describing the characteristics, beliefs, and expectations of each of these groups, this book intends to support both entrepreneurs and investors in getting along more successfully with each other. At the end of the day, finding the most suitable partner and building a relationship based on mutual understanding greatly increases the chances of a biotech start-up to succeed in a fiercely fought-over market.

N.B.: For easier reading, only male titles were used.



## Acknowledgments

I would like to take the opportunity to thank a lot of people who have, directly or indirectly, been involved in writing this book.

First of all, I would like to extend a warm thank you to Professor Thomas Hellmann from the University of British Columbia (UBC), Vancouver ([www.strategy.sauder.ubc.ca/hellmann/](http://www.strategy.sauder.ubc.ca/hellmann/)). It was more than an exciting experience to work with Thomas on the development of my master thesis, both conceptually and practically. Thomas gave me lots of insights into the world of global venture capital. First inspired by the issue during Thomas' lectures in November 2006, the idea of writing a thesis – and later this book – on venture capitalism has now come to fruition.

Second, I would like to thank all of my interview partners, without whom this book would not have been possible. It was exciting and challenging to interview so many highly experienced entrepreneurs, venture capitalists, and other experts and investors, and discuss their insights into the European biotech market and the financing models available to develop a company. Every single interview contributed distinctively to the overall conclusions of this work, which would have been unthinkable without their generous and valuable support. Special thanks go to the contributors of the extended biotech case studies presented in this book, namely to Thomas Fischer and Susanne Bach of AUSTRIANOVA Biomanufacturing AG, Michael Tscheppe, Reinhard Zickler, and Isolde Bergmann of AVIR Green Hills Biotechnology AG, Wolfgang Schönfeld of EUCODIS GmbH, Werner Lanthaler of Intercell AG, and Bernhard Küenburg of onepharm GmbH.

Last but not least, I wish to thank my parents, who have given me unlimited support both during my educational and professional career and while writing this book. I feel privileged to have been able to receive such high-level education, and I believe this journey is bound to continue.

Moreover, representative of the many friends and colleagues who supported me, let me mention my friend and English editor Gabi ([www.the-text-clinic.com](http://www.the-text-clinic.com)), my graphic artist Alexander ([www.schatek.at](http://www.schatek.at)), my friend and former classmate Teodoro, and my good old friend Herbert. It is an incredible gift to be able to rely on the knowledge of such highly experienced and talented friends. While working

on this book, I was able to follow their recommendations in so many different ways.

Therefore, dear reader, please consider this piece of work a heartfelt thank you to my instructor, to my many interview partners, and to my family and friends. Thank you all – and please enjoy reading!

Vienna, July 2008

*Alexandra Carina Gruber*

## Limit of Liability/Disclaimer of Warranty

While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the content of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. Rather, the assumptions expressed in this book reflect the personal interpretation of the authors and are subject to the continuous changes of research, (clinical) experience, and scientific opinion. The advice and strategies contained herein may not be suitable for the reader's situation, who should consult with a professional, where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Designations used by companies to distinguish their products are often claimed as trademarks. In all instances where John Wiley & Sons, Inc., is aware of a claim, the product name appears with initial capital or all capital letters. Readers, however, should contact the appropriate companies for more complete information regarding trademarks and registration. The absence of trademark or registration symbols should not be taken to indicate absence of trademark protection; anyone wishing to use product names in the public domain should first clear such use with the product owner.

All websites mentioned as references were accessed between January and July 2008.



## Executive Summary

The European biotech industry has long lagged behind its US counterpart. For most of Europe, the same was true for private equity and venture capital spending on innovative start-ups. In recent years, however, the European biotech industry has improved its competitive position vis-à-vis the US, and so has the development of the private equity and venture capital market. Despite this positive trend, only a small fraction of available capital is invested in biotech – probably because there is hardly an area more complex, more globally oriented, more time-consuming, and more risky. As a result, many biotech start-ups today are still struggling for survival, particularly in cultures that are less entrepreneurially and private-equity driven, such as Austria and Germany, where there is still an evident gap between seed and early-stage financing. Considering the long lead times involved in biotechnological research and development, the unwillingness of venture capitalists to fund early development may largely be due to start-ups being unable to propose viable exits. At the same time, it has become tougher for companies to raise venture capital, as consolidation has thinned the ranks of venture capital firms.

This book focuses on two counteracting trends: One is the private equity and venture capital spending boom and the increasing number of biotech start-ups with strong product pipelines. At the same time, compared to other industries, the amount of venture capital spent on biotech start-ups is still limited.

In general, each development phase of a young company is financed by specific types of investors. In the preseed and seed phases, financing in many cases starts with the ‘three Fs’ – family, friends, and fools. After that, it is usually the government that steps in with grants and loans, followed by business angels and early-stage venture capitalists. In later development stages and as capital requirements increase, strategic alliances with corporate companies are key to success, as are deals with late-stage venture capitalists or banks. The last link in the financing chain of a biotech start-up is its exit, usually in form of an initial public offering (IPO), trade sale, or management buy-out.

Based on the general financing matrix for start-up companies and given the complexity of biotech development, the primary question of this survey was whether a biotech start-up went through the same development phases and was financed by